XNTR 956
Alternative Names: XNTR-956Latest Information Update: 19 May 2021
At a glance
- Originator Xennials Therapeutics
- Class Antineoplastics
- Mechanism of Action STAT transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 05 May 2021 XNTR 956 is available for licensing as of 04 May 2021. https://xennialstherapeutics.com/contact-us/
- 04 May 2021 Early research in Haematological malignancies in USA (unspecified route) before May 2021 (Xennials Therapeutics pipeline, May 2021)
- 04 May 2021 Early research in Solid tumours in USA (unspecified route) before May 2021 (Xennials Therapeutics pipeline, May 2021)